Efficient delivery of
oligonucleotides still remains a challenge in the field of
oligonucleotide based
therapy.
Peptide nucleic acid (PNA),
a DNA analogue that is typically synthesized by solid phase
peptide chemistry, has been conjugated to a variety of
cell penetrating peptides (
CPP) as a means of improving its cellular uptake. These CPPs typically deliver their cargoes into cells by an endosomal-dependent mechanism resulting in lower bioavailability of the cargo. Herein, we designed and synthesized PNA-
peptide conjugates as splice switching
oligonucleotides (SSO) targeting the Mnk2 gene, a therapeutic target in
cancer. In humans, the MKNK2 gene, is alternatively spliced, generating
isoforms with opposite biological activities: Mnk2a and Mnk2b. It was found that the Mnk2a
isoform is down-regulated in breast, lung, brain, and colon
tumors and is a
tumor suppressor, whereas MnK2b is oncogenic. We have designed and synthesized PNAs that were conjugated to either of the following
peptides: a nuclear localization sequence (NLS) or a cytosol localizing internalization
peptide (CLIP6). CLIP6-PNA demonstrates effective cellular uptake and exclusively employs a nonendosomal mechanism to cross the cellular membranes of
glioblastoma cells (U87). Simple incubation of PNA-
peptide conjugates in human
glioblastoma cells up-regulates the Mnk2a
isoform leading to
cancer cell death.